About Clozaril | Videos | CSAN Pronto
Clozaril® (clozapine) is indicated in the management of symptoms of treatment-resistant schizophrenia. In controlled clinical trials, clozapine was found to improve both positive and negative symptoms.1
Please consult the CLOZARIL® Product Monograph at http://www.hlstherapeutics.com/wp-content/uploads/monograph_pdf/HLS-Clozaril-PM-E.pdf for contraindications, warnings, precautions, adverse reactions, drug interactions (particularly CYP 450 isoenzymes inhibitors or inducers drugs), dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-267-2726.
Reference:
1. Clozaril® Product Monograph. HLS Therapeutics Inc. July 10, 2025.
For Canadian Residents Only | Français
Resources for Healthcare Professionals
The following resources provide information on CLOZARIL® and the CLOZARIL® Support and Assistance Network® (CSAN®).
CSAN® Enrolment Form
Consent must be obtained from all CLOZARIL® patients. Registration of CLOZARIL® patients, treating physician, testing laboratory and dispensing pharmacist in the CSAN® system is also required.1
Download the CSAN® form to enroll your patients.
CSAN® Booklet
Explore CSAN®’s wide range of services for CLOZARIL®-treated patients and their families.
CLOZARIL®-CSAN®
Hematological Quick
Reference Chart
Explore CSAN®’s wide range of services for CLOZARIL®-treated patients and their families.